ReviewAnnals of neurology2014
Quantifying disease progression in amyotrophic lateral sclerosis.
Review in Annals of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological Quality of Clinical Trials in Amyotrophic Lateral Sclerosis: A Systematic Review.Journal of neuromuscular diseases · 2024Pooled it
- Clinical and literature insights into the frontotemporal dementia and motor neuron disease spectrum.Discover mental health · 2026Article
- Neutrophil-to-lymphocyte ratio in amyotrophic lateral sclerosis: a systematic review and meta-analysis.Brain communications · 2026Review
- An organ-chip model of sporadic ALS using iPSC-derived spinal cord motor neurons and an integrated blood-brain-like barrier.Cell stem cell · 2025Article
- Intramuscular Nerve Bundles Reflect TDP-43 Pathology in the Medulla and Spinal Cord of ALS Patients.Neuropathology and applied neurobiology · 2025Article
- Is there a decline in speech and swallowing in Amyotrophic Lateral Sclerosis over ten years?CoDAS · 2025Article
- T1-relaxation times along the corticospinal tract as a diagnostic marker in patients with amyotrophic lateral sclerosis.Frontiers in neuroimaging · 2025Article
- Analysis of Mortality Causes and Locations in Veterans with ALS: A Decade Review.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- TDP43 aggregation at ER-exit sites impairs ER-to-Golgi transport.Nature communications · 2024Article
- Diffusion tensor imaging biomarkers and clinical assessments in amyotrophic lateral sclerosis (ALS) patients: an exploratory study.Annals of medicine and surgery (2012) · 2024Article
- T1-weighted MRI texture analysis in amyotrophic lateral sclerosis patients stratified by the D50 progression model.Brain communications · 2024Article
- Exploring Relevant Time Windows in the Association Between PM2.5 Exposure and Amyotrophic Lateral Sclerosis: A Case-Control Study in Denmark.American journal of epidemiology · 2023Article
- Hippocampal Metabolic Alterations in Amyotrophic Lateral Sclerosis: A Magnetic Resonance Spectroscopy Study.Life (Basel, Switzerland) · 2023Article
- Staging model for amyotrophic lateral sclerosis in Singapore.Singapore medical journal · 2022Article
- Swallowing Safety and Efficiency Impairment Profiles in Individuals with Amyotrophic Lateral Sclerosis.Dysphagia · 2022Article
- PMEnvironmental epidemiology (Philadelphia, Pa.) · 2022Article
- Affection of Respiratory Muscles in ALS and SMA.Journal of clinical medicine · 2022Article
- Classification of amyotrophic lateral sclerosis by brain volume, connectivity, and network dynamics.Human brain mapping · 2022Article
- Neutrophils-to-Lymphocyte Ratio Is Associated with Progression and Overall Survival in Amyotrophic Lateral Sclerosis.Biomedicines · 2022Article
- Assistive Technologies for Communication Empower Patients With ALS to Generate and Self-Report Health Data.Frontiers in neurology · 2022Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Amyotrophic lateral sclerosis (ALS) exhibits characteristic variability of onset and rate of disease progression, with inherent clinical heterogeneity making disease quantitation difficult. Recent advances in understanding pathogenic mechanisms linked to the development of ALS impose an increasing need to develop strategies to predict and more objectively measure disease progression. This review explores phenotypic and genetic determinants of disease progression in ALS, and examines established and evolving biomarkers that may contribute to robust measurement in longitudinal clinical studies. With targeted neuroprotective strategies on the horizon, developing efficiencies in clinical trial design may facilitate timely entry of novel treatments into the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.